nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP2C8—Fluorouracil—colon cancer	0.022	0.558	CbGbCtD
Trametinib—MAP2K1—embryo—colon cancer	0.0114	0.0944	CbGeAlD
Trametinib—CYP3A4—Irinotecan—colon cancer	0.0093	0.236	CbGbCtD
Trametinib—MAP2K1—epithelium—colon cancer	0.00927	0.077	CbGeAlD
Trametinib—MAP2K1—smooth muscle tissue—colon cancer	0.00894	0.0742	CbGeAlD
Trametinib—MAP2K1—renal system—colon cancer	0.0086	0.0714	CbGeAlD
Trametinib—CYP3A4—Vincristine—colon cancer	0.00813	0.206	CbGbCtD
Trametinib—MAP2K2—smooth muscle tissue—colon cancer	0.00787	0.0653	CbGeAlD
Trametinib—MAP2K2—renal system—colon cancer	0.00757	0.0629	CbGeAlD
Trametinib—MAP2K1—lymphoid tissue—colon cancer	0.00714	0.0593	CbGeAlD
Trametinib—MAP2K1—digestive system—colon cancer	0.00706	0.0586	CbGeAlD
Trametinib—MAP2K1—bone marrow—colon cancer	0.0065	0.054	CbGeAlD
Trametinib—MAP2K2—lymphoid tissue—colon cancer	0.00629	0.0522	CbGeAlD
Trametinib—MAP2K2—digestive system—colon cancer	0.00621	0.0516	CbGeAlD
Trametinib—MAP2K2—bone marrow—colon cancer	0.00573	0.0475	CbGeAlD
Trametinib—MAP2K1—liver—colon cancer	0.00526	0.0436	CbGeAlD
Trametinib—MAP2K2—liver—colon cancer	0.00463	0.0384	CbGeAlD
Trametinib—MAP2K1—lymph node—colon cancer	0.00403	0.0335	CbGeAlD
Trametinib—MAP2K2—lymph node—colon cancer	0.00355	0.0295	CbGeAlD
Trametinib—CYP2C8—renal system—colon cancer	0.00262	0.0218	CbGeAlD
Trametinib—CYP2C8—vagina—colon cancer	0.0019	0.0158	CbGeAlD
Trametinib—CYP3A4—renal system—colon cancer	0.00178	0.0147	CbGeAlD
Trametinib—CYP2C8—liver—colon cancer	0.0016	0.0133	CbGeAlD
Trametinib—Hyponatraemia—Irinotecan—colon cancer	0.00155	0.00467	CcSEcCtD
Trametinib—Dehydration—Vincristine—colon cancer	0.00148	0.00444	CcSEcCtD
Trametinib—CYP3A4—digestive system—colon cancer	0.00146	0.0121	CbGeAlD
Trametinib—Blood creatinine increased—Irinotecan—colon cancer	0.00145	0.00436	CcSEcCtD
Trametinib—Dehydration—Irinotecan—colon cancer	0.00144	0.00433	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Vincristine—colon cancer	0.00143	0.0043	CcSEcCtD
Trametinib—Phosphatase alkaline increased—Capecitabine—colon cancer	0.00143	0.00429	CcSEcCtD
Trametinib—Hypokalaemia—Irinotecan—colon cancer	0.00141	0.00423	CcSEcCtD
Trametinib—Melaena—Capecitabine—colon cancer	0.00139	0.00419	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Irinotecan—colon cancer	0.00139	0.00419	CcSEcCtD
Trametinib—Dry skin—Fluorouracil—colon cancer	0.00136	0.00408	CcSEcCtD
Trametinib—Dry eye—Capecitabine—colon cancer	0.00132	0.00396	CcSEcCtD
Trametinib—Pancreatitis—Irinotecan—colon cancer	0.00131	0.00394	CcSEcCtD
Trametinib—Neoplasm—Capecitabine—colon cancer	0.00129	0.00388	CcSEcCtD
Trametinib—Mouth ulceration—Capecitabine—colon cancer	0.00129	0.00388	CcSEcCtD
Trametinib—Neutropenia—Vincristine—colon cancer	0.00128	0.00386	CcSEcCtD
Trametinib—Neutropenia—Irinotecan—colon cancer	0.00125	0.00376	CcSEcCtD
Trametinib—Stomatitis—Vincristine—colon cancer	0.00119	0.00359	CcSEcCtD
Trametinib—Blood alkaline phosphatase increased—Capecitabine—colon cancer	0.00119	0.00358	CcSEcCtD
Trametinib—Bone disorder—Methotrexate—colon cancer	0.00118	0.00354	CcSEcCtD
Trametinib—Renal failure—Irinotecan—colon cancer	0.00117	0.00352	CcSEcCtD
Trametinib—Hyperbilirubinaemia—Methotrexate—colon cancer	0.00117	0.00351	CcSEcCtD
Trametinib—Stomatitis—Irinotecan—colon cancer	0.00116	0.00349	CcSEcCtD
Trametinib—Infestation NOS—Fluorouracil—colon cancer	0.00114	0.00343	CcSEcCtD
Trametinib—Infestation—Fluorouracil—colon cancer	0.00114	0.00343	CcSEcCtD
Trametinib—Renal failure acute—Capecitabine—colon cancer	0.00112	0.00337	CcSEcCtD
Trametinib—Stomatitis—Fluorouracil—colon cancer	0.00111	0.00335	CcSEcCtD
Trametinib—Urinary tract infection—Fluorouracil—colon cancer	0.00111	0.00334	CcSEcCtD
Trametinib—Bradycardia—Irinotecan—colon cancer	0.00109	0.00328	CcSEcCtD
Trametinib—Urinary tract disorder—Vincristine—colon cancer	0.00109	0.00326	CcSEcCtD
Trametinib—CYP3A4—liver—colon cancer	0.00109	0.00901	CbGeAlD
Trametinib—Connective tissue disorder—Vincristine—colon cancer	0.00108	0.00325	CcSEcCtD
Trametinib—Urethral disorder—Vincristine—colon cancer	0.00108	0.00324	CcSEcCtD
Trametinib—Epistaxis—Fluorouracil—colon cancer	0.00108	0.00324	CcSEcCtD
Trametinib—Haemoglobin—Irinotecan—colon cancer	0.00108	0.00324	CcSEcCtD
Trametinib—Haemorrhage—Irinotecan—colon cancer	0.00107	0.00322	CcSEcCtD
Trametinib—Connective tissue disorder—Irinotecan—colon cancer	0.00105	0.00316	CcSEcCtD
Trametinib—Hyponatraemia—Capecitabine—colon cancer	0.00104	0.00313	CcSEcCtD
Trametinib—Melaena—Methotrexate—colon cancer	0.00104	0.00312	CcSEcCtD
Trametinib—Pain in extremity—Capecitabine—colon cancer	0.00104	0.00311	CcSEcCtD
Trametinib—Haemoglobin—Fluorouracil—colon cancer	0.00103	0.0031	CcSEcCtD
Trametinib—Haemorrhage—Fluorouracil—colon cancer	0.00103	0.00308	CcSEcCtD
Trametinib—Cardiac disorder—Vincristine—colon cancer	0.00102	0.00307	CcSEcCtD
Trametinib—Angiopathy—Vincristine—colon cancer	0.000997	0.003	CcSEcCtD
Trametinib—Cardiac disorder—Irinotecan—colon cancer	0.000993	0.00299	CcSEcCtD
Trametinib—Mediastinal disorder—Vincristine—colon cancer	0.000991	0.00298	CcSEcCtD
Trametinib—Angiopathy—Irinotecan—colon cancer	0.000971	0.00292	CcSEcCtD
Trametinib—Blood creatinine increased—Capecitabine—colon cancer	0.00097	0.00292	CcSEcCtD
Trametinib—Mediastinal disorder—Irinotecan—colon cancer	0.000965	0.0029	CcSEcCtD
Trametinib—Dehydration—Capecitabine—colon cancer	0.000963	0.0029	CcSEcCtD
Trametinib—Mental disorder—Vincristine—colon cancer	0.000963	0.0029	CcSEcCtD
Trametinib—Chills—Irinotecan—colon cancer	0.000961	0.00289	CcSEcCtD
Trametinib—Mouth ulceration—Methotrexate—colon cancer	0.00096	0.00289	CcSEcCtD
Trametinib—Neoplasm—Methotrexate—colon cancer	0.00096	0.00289	CcSEcCtD
Trametinib—Arrhythmia—Irinotecan—colon cancer	0.000956	0.00288	CcSEcCtD
Trametinib—Dry skin—Capecitabine—colon cancer	0.000949	0.00285	CcSEcCtD
Trametinib—Abdominal pain upper—Capecitabine—colon cancer	0.000946	0.00284	CcSEcCtD
Trametinib—Hypokalaemia—Capecitabine—colon cancer	0.000943	0.00283	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Capecitabine—colon cancer	0.000933	0.0028	CcSEcCtD
Trametinib—Back pain—Vincristine—colon cancer	0.000926	0.00278	CcSEcCtD
Trametinib—Arrhythmia—Fluorouracil—colon cancer	0.000916	0.00275	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Capecitabine—colon cancer	0.000913	0.00275	CcSEcCtD
Trametinib—Back pain—Irinotecan—colon cancer	0.000901	0.00271	CcSEcCtD
Trametinib—Muscle spasms—Irinotecan—colon cancer	0.000896	0.00269	CcSEcCtD
Trametinib—Erythema—Fluorouracil—colon cancer	0.000893	0.00268	CcSEcCtD
Trametinib—Anaemia—Vincristine—colon cancer	0.000884	0.00266	CcSEcCtD
Trametinib—Anaemia—Irinotecan—colon cancer	0.000861	0.00259	CcSEcCtD
Trametinib—Abdominal discomfort—Capecitabine—colon cancer	0.000858	0.00258	CcSEcCtD
Trametinib—Leukopenia—Vincristine—colon cancer	0.000857	0.00258	CcSEcCtD
Trametinib—Vision blurred—Fluorouracil—colon cancer	0.000841	0.00253	CcSEcCtD
Trametinib—Neutropenia—Capecitabine—colon cancer	0.000837	0.00252	CcSEcCtD
Trametinib—Renal failure acute—Methotrexate—colon cancer	0.000835	0.00251	CcSEcCtD
Trametinib—Leukopenia—Irinotecan—colon cancer	0.000834	0.00251	CcSEcCtD
Trametinib—Hypertension—Vincristine—colon cancer	0.000826	0.00248	CcSEcCtD
Trametinib—Anaemia—Fluorouracil—colon cancer	0.000825	0.00248	CcSEcCtD
Trametinib—Myalgia—Vincristine—colon cancer	0.000815	0.00245	CcSEcCtD
Trametinib—Cough—Irinotecan—colon cancer	0.000813	0.00245	CcSEcCtD
Trametinib—Hyperglycaemia—Capecitabine—colon cancer	0.000807	0.00243	CcSEcCtD
Trametinib—Hypertension—Irinotecan—colon cancer	0.000805	0.00242	CcSEcCtD
Trametinib—Leukopenia—Fluorouracil—colon cancer	0.000799	0.0024	CcSEcCtD
Trametinib—Infestation NOS—Capecitabine—colon cancer	0.000798	0.0024	CcSEcCtD
Trametinib—Infestation—Capecitabine—colon cancer	0.000798	0.0024	CcSEcCtD
Trametinib—Renal failure—Capecitabine—colon cancer	0.000785	0.00236	CcSEcCtD
Trametinib—Oedema—Vincristine—colon cancer	0.000781	0.00235	CcSEcCtD
Trametinib—Stomatitis—Capecitabine—colon cancer	0.000778	0.00234	CcSEcCtD
Trametinib—Infection—Vincristine—colon cancer	0.000776	0.00233	CcSEcCtD
Trametinib—Urinary tract infection—Capecitabine—colon cancer	0.000776	0.00233	CcSEcCtD
Trametinib—Nervous system disorder—Vincristine—colon cancer	0.000766	0.0023	CcSEcCtD
Trametinib—Thrombocytopenia—Vincristine—colon cancer	0.000765	0.0023	CcSEcCtD
Trametinib—Haematuria—Capecitabine—colon cancer	0.000761	0.00229	CcSEcCtD
Trametinib—Oedema—Irinotecan—colon cancer	0.000761	0.00229	CcSEcCtD
Trametinib—Myalgia—Fluorouracil—colon cancer	0.00076	0.00228	CcSEcCtD
Trametinib—Infection—Irinotecan—colon cancer	0.000756	0.00227	CcSEcCtD
Trametinib—Hyperhidrosis—Vincristine—colon cancer	0.000755	0.00227	CcSEcCtD
Trametinib—Epistaxis—Capecitabine—colon cancer	0.000753	0.00226	CcSEcCtD
Trametinib—Nervous system disorder—Irinotecan—colon cancer	0.000746	0.00224	CcSEcCtD
Trametinib—Thrombocytopenia—Irinotecan—colon cancer	0.000745	0.00224	CcSEcCtD
Trametinib—Hyperhidrosis—Irinotecan—colon cancer	0.000735	0.00221	CcSEcCtD
Trametinib—Bradycardia—Capecitabine—colon cancer	0.000729	0.00219	CcSEcCtD
Trametinib—Oedema—Fluorouracil—colon cancer	0.000728	0.00219	CcSEcCtD
Trametinib—Infection—Fluorouracil—colon cancer	0.000724	0.00218	CcSEcCtD
Trametinib—Haemoglobin—Capecitabine—colon cancer	0.00072	0.00217	CcSEcCtD
Trametinib—Haemorrhage—Capecitabine—colon cancer	0.000716	0.00215	CcSEcCtD
Trametinib—Nervous system disorder—Fluorouracil—colon cancer	0.000714	0.00215	CcSEcCtD
Trametinib—Thrombocytopenia—Fluorouracil—colon cancer	0.000713	0.00214	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Vincristine—colon cancer	0.000711	0.00214	CcSEcCtD
Trametinib—Urinary tract disorder—Capecitabine—colon cancer	0.000708	0.00213	CcSEcCtD
Trametinib—Insomnia—Vincristine—colon cancer	0.000706	0.00212	CcSEcCtD
Trametinib—Oedema peripheral—Capecitabine—colon cancer	0.000706	0.00212	CcSEcCtD
Trametinib—Connective tissue disorder—Capecitabine—colon cancer	0.000704	0.00212	CcSEcCtD
Trametinib—Urethral disorder—Capecitabine—colon cancer	0.000702	0.00211	CcSEcCtD
Trametinib—Insomnia—Irinotecan—colon cancer	0.000688	0.00207	CcSEcCtD
Trametinib—Decreased appetite—Vincristine—colon cancer	0.000679	0.00204	CcSEcCtD
Trametinib—Gastrointestinal disorder—Vincristine—colon cancer	0.000674	0.00203	CcSEcCtD
Trametinib—Fatigue—Vincristine—colon cancer	0.000673	0.00202	CcSEcCtD
Trametinib—Eye disorder—Capecitabine—colon cancer	0.00067	0.00201	CcSEcCtD
Trametinib—Constipation—Vincristine—colon cancer	0.000668	0.00201	CcSEcCtD
Trametinib—Cardiac disorder—Capecitabine—colon cancer	0.000665	0.002	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000664	0.002	CcSEcCtD
Trametinib—Decreased appetite—Irinotecan—colon cancer	0.000661	0.00199	CcSEcCtD
Trametinib—Insomnia—Fluorouracil—colon cancer	0.000659	0.00198	CcSEcCtD
Trametinib—Gastrointestinal disorder—Irinotecan—colon cancer	0.000657	0.00197	CcSEcCtD
Trametinib—Fatigue—Irinotecan—colon cancer	0.000656	0.00197	CcSEcCtD
Trametinib—Pancreatitis—Methotrexate—colon cancer	0.000653	0.00196	CcSEcCtD
Trametinib—Constipation—Irinotecan—colon cancer	0.00065	0.00196	CcSEcCtD
Trametinib—Angiopathy—Capecitabine—colon cancer	0.00065	0.00195	CcSEcCtD
Trametinib—Mediastinal disorder—Capecitabine—colon cancer	0.000646	0.00194	CcSEcCtD
Trametinib—Chills—Capecitabine—colon cancer	0.000643	0.00193	CcSEcCtD
Trametinib—Arrhythmia—Capecitabine—colon cancer	0.00064	0.00192	CcSEcCtD
Trametinib—Abdominal discomfort—Methotrexate—colon cancer	0.000639	0.00192	CcSEcCtD
Trametinib—Gastrointestinal pain—Vincristine—colon cancer	0.000639	0.00192	CcSEcCtD
Trametinib—Decreased appetite—Fluorouracil—colon cancer	0.000633	0.0019	CcSEcCtD
Trametinib—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000629	0.00189	CcSEcCtD
Trametinib—Mental disorder—Capecitabine—colon cancer	0.000628	0.00189	CcSEcCtD
Trametinib—Malnutrition—Capecitabine—colon cancer	0.000624	0.00188	CcSEcCtD
Trametinib—Erythema—Capecitabine—colon cancer	0.000624	0.00188	CcSEcCtD
Trametinib—Neutropenia—Methotrexate—colon cancer	0.000623	0.00187	CcSEcCtD
Trametinib—Gastrointestinal pain—Irinotecan—colon cancer	0.000622	0.00187	CcSEcCtD
Trametinib—Body temperature increased—Vincristine—colon cancer	0.000617	0.00186	CcSEcCtD
Trametinib—Abdominal pain—Vincristine—colon cancer	0.000617	0.00186	CcSEcCtD
Trametinib—Dysgeusia—Capecitabine—colon cancer	0.000611	0.00184	CcSEcCtD
Trametinib—Back pain—Capecitabine—colon cancer	0.000603	0.00181	CcSEcCtD
Trametinib—Abdominal pain—Irinotecan—colon cancer	0.000601	0.00181	CcSEcCtD
Trametinib—Body temperature increased—Irinotecan—colon cancer	0.000601	0.00181	CcSEcCtD
Trametinib—Muscle spasms—Capecitabine—colon cancer	0.0006	0.0018	CcSEcCtD
Trametinib—Infestation NOS—Methotrexate—colon cancer	0.000594	0.00179	CcSEcCtD
Trametinib—Infestation—Methotrexate—colon cancer	0.000594	0.00179	CcSEcCtD
Trametinib—Vision blurred—Capecitabine—colon cancer	0.000588	0.00177	CcSEcCtD
Trametinib—Renal failure—Methotrexate—colon cancer	0.000584	0.00176	CcSEcCtD
Trametinib—Stomatitis—Methotrexate—colon cancer	0.000579	0.00174	CcSEcCtD
Trametinib—Anaemia—Capecitabine—colon cancer	0.000576	0.00173	CcSEcCtD
Trametinib—Body temperature increased—Fluorouracil—colon cancer	0.000576	0.00173	CcSEcCtD
Trametinib—Haematuria—Methotrexate—colon cancer	0.000566	0.0017	CcSEcCtD
Trametinib—Epistaxis—Methotrexate—colon cancer	0.00056	0.00168	CcSEcCtD
Trametinib—Asthenia—Vincristine—colon cancer	0.00056	0.00168	CcSEcCtD
Trametinib—Leukopenia—Capecitabine—colon cancer	0.000558	0.00168	CcSEcCtD
Trametinib—Asthenia—Irinotecan—colon cancer	0.000546	0.00164	CcSEcCtD
Trametinib—Cough—Capecitabine—colon cancer	0.000544	0.00164	CcSEcCtD
Trametinib—Hypertension—Capecitabine—colon cancer	0.000538	0.00162	CcSEcCtD
Trametinib—Haemoglobin—Methotrexate—colon cancer	0.000536	0.00161	CcSEcCtD
Trametinib—Diarrhoea—Vincristine—colon cancer	0.000534	0.00161	CcSEcCtD
Trametinib—Haemorrhage—Methotrexate—colon cancer	0.000533	0.0016	CcSEcCtD
Trametinib—Myalgia—Capecitabine—colon cancer	0.000531	0.0016	CcSEcCtD
Trametinib—Arthralgia—Capecitabine—colon cancer	0.000531	0.0016	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000527	0.00159	CcSEcCtD
Trametinib—Urinary tract disorder—Methotrexate—colon cancer	0.000527	0.00158	CcSEcCtD
Trametinib—Urethral disorder—Methotrexate—colon cancer	0.000523	0.00157	CcSEcCtD
Trametinib—Diarrhoea—Irinotecan—colon cancer	0.00052	0.00156	CcSEcCtD
Trametinib—Dry mouth—Capecitabine—colon cancer	0.000519	0.00156	CcSEcCtD
Trametinib—Dizziness—Vincristine—colon cancer	0.000516	0.00155	CcSEcCtD
Trametinib—Pruritus—Fluorouracil—colon cancer	0.000515	0.00155	CcSEcCtD
Trametinib—Oedema—Capecitabine—colon cancer	0.000509	0.00153	CcSEcCtD
Trametinib—Infection—Capecitabine—colon cancer	0.000506	0.00152	CcSEcCtD
Trametinib—Dizziness—Irinotecan—colon cancer	0.000503	0.00151	CcSEcCtD
Trametinib—Nervous system disorder—Capecitabine—colon cancer	0.000499	0.0015	CcSEcCtD
Trametinib—Eye disorder—Methotrexate—colon cancer	0.000498	0.0015	CcSEcCtD
Trametinib—Diarrhoea—Fluorouracil—colon cancer	0.000498	0.0015	CcSEcCtD
Trametinib—Thrombocytopenia—Capecitabine—colon cancer	0.000498	0.0015	CcSEcCtD
Trametinib—Vomiting—Vincristine—colon cancer	0.000497	0.00149	CcSEcCtD
Trametinib—Cardiac disorder—Methotrexate—colon cancer	0.000495	0.00149	CcSEcCtD
Trametinib—Skin disorder—Capecitabine—colon cancer	0.000494	0.00149	CcSEcCtD
Trametinib—Rash—Vincristine—colon cancer	0.000492	0.00148	CcSEcCtD
Trametinib—Hyperhidrosis—Capecitabine—colon cancer	0.000492	0.00148	CcSEcCtD
Trametinib—Dermatitis—Vincristine—colon cancer	0.000492	0.00148	CcSEcCtD
Trametinib—Headache—Vincristine—colon cancer	0.000489	0.00147	CcSEcCtD
Trametinib—Angiopathy—Methotrexate—colon cancer	0.000484	0.00146	CcSEcCtD
Trametinib—Vomiting—Irinotecan—colon cancer	0.000484	0.00145	CcSEcCtD
Trametinib—Dizziness—Fluorouracil—colon cancer	0.000482	0.00145	CcSEcCtD
Trametinib—Mediastinal disorder—Methotrexate—colon cancer	0.000481	0.00145	CcSEcCtD
Trametinib—Rash—Irinotecan—colon cancer	0.00048	0.00144	CcSEcCtD
Trametinib—Dermatitis—Irinotecan—colon cancer	0.000479	0.00144	CcSEcCtD
Trametinib—Chills—Methotrexate—colon cancer	0.000479	0.00144	CcSEcCtD
Trametinib—Headache—Irinotecan—colon cancer	0.000476	0.00143	CcSEcCtD
Trametinib—Mental disorder—Methotrexate—colon cancer	0.000467	0.0014	CcSEcCtD
Trametinib—Malnutrition—Methotrexate—colon cancer	0.000464	0.0014	CcSEcCtD
Trametinib—Erythema—Methotrexate—colon cancer	0.000464	0.0014	CcSEcCtD
Trametinib—Nausea—Vincristine—colon cancer	0.000464	0.00139	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000464	0.00139	CcSEcCtD
Trametinib—Vomiting—Fluorouracil—colon cancer	0.000463	0.00139	CcSEcCtD
Trametinib—Insomnia—Capecitabine—colon cancer	0.00046	0.00138	CcSEcCtD
Trametinib—Rash—Fluorouracil—colon cancer	0.000459	0.00138	CcSEcCtD
Trametinib—Dermatitis—Fluorouracil—colon cancer	0.000459	0.00138	CcSEcCtD
Trametinib—Headache—Fluorouracil—colon cancer	0.000456	0.00137	CcSEcCtD
Trametinib—Dysgeusia—Methotrexate—colon cancer	0.000455	0.00137	CcSEcCtD
Trametinib—Nausea—Irinotecan—colon cancer	0.000452	0.00136	CcSEcCtD
Trametinib—Back pain—Methotrexate—colon cancer	0.000449	0.00135	CcSEcCtD
Trametinib—Decreased appetite—Capecitabine—colon cancer	0.000442	0.00133	CcSEcCtD
Trametinib—Gastrointestinal disorder—Capecitabine—colon cancer	0.000439	0.00132	CcSEcCtD
Trametinib—Fatigue—Capecitabine—colon cancer	0.000439	0.00132	CcSEcCtD
Trametinib—Vision blurred—Methotrexate—colon cancer	0.000438	0.00132	CcSEcCtD
Trametinib—Constipation—Capecitabine—colon cancer	0.000435	0.00131	CcSEcCtD
Trametinib—Nausea—Fluorouracil—colon cancer	0.000433	0.0013	CcSEcCtD
Trametinib—Anaemia—Methotrexate—colon cancer	0.000429	0.00129	CcSEcCtD
Trametinib—Gastrointestinal pain—Capecitabine—colon cancer	0.000416	0.00125	CcSEcCtD
Trametinib—Leukopenia—Methotrexate—colon cancer	0.000416	0.00125	CcSEcCtD
Trametinib—Cough—Methotrexate—colon cancer	0.000405	0.00122	CcSEcCtD
Trametinib—Body temperature increased—Capecitabine—colon cancer	0.000402	0.00121	CcSEcCtD
Trametinib—Abdominal pain—Capecitabine—colon cancer	0.000402	0.00121	CcSEcCtD
Trametinib—Myalgia—Methotrexate—colon cancer	0.000395	0.00119	CcSEcCtD
Trametinib—Arthralgia—Methotrexate—colon cancer	0.000395	0.00119	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000393	0.00118	CcSEcCtD
Trametinib—Infection—Methotrexate—colon cancer	0.000376	0.00113	CcSEcCtD
Trametinib—Nervous system disorder—Methotrexate—colon cancer	0.000372	0.00112	CcSEcCtD
Trametinib—Thrombocytopenia—Methotrexate—colon cancer	0.000371	0.00112	CcSEcCtD
Trametinib—Skin disorder—Methotrexate—colon cancer	0.000368	0.00111	CcSEcCtD
Trametinib—Hyperhidrosis—Methotrexate—colon cancer	0.000366	0.0011	CcSEcCtD
Trametinib—Asthenia—Capecitabine—colon cancer	0.000365	0.0011	CcSEcCtD
Trametinib—Pruritus—Capecitabine—colon cancer	0.00036	0.00108	CcSEcCtD
Trametinib—Diarrhoea—Capecitabine—colon cancer	0.000348	0.00105	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000345	0.00104	CcSEcCtD
Trametinib—Insomnia—Methotrexate—colon cancer	0.000343	0.00103	CcSEcCtD
Trametinib—Dizziness—Capecitabine—colon cancer	0.000337	0.00101	CcSEcCtD
Trametinib—Decreased appetite—Methotrexate—colon cancer	0.000329	0.00099	CcSEcCtD
Trametinib—Gastrointestinal disorder—Methotrexate—colon cancer	0.000327	0.000984	CcSEcCtD
Trametinib—Fatigue—Methotrexate—colon cancer	0.000327	0.000982	CcSEcCtD
Trametinib—Vomiting—Capecitabine—colon cancer	0.000324	0.000973	CcSEcCtD
Trametinib—Rash—Capecitabine—colon cancer	0.000321	0.000965	CcSEcCtD
Trametinib—Dermatitis—Capecitabine—colon cancer	0.000321	0.000964	CcSEcCtD
Trametinib—Headache—Capecitabine—colon cancer	0.000319	0.000959	CcSEcCtD
Trametinib—Gastrointestinal pain—Methotrexate—colon cancer	0.00031	0.000932	CcSEcCtD
Trametinib—Nausea—Capecitabine—colon cancer	0.000302	0.000909	CcSEcCtD
Trametinib—Abdominal pain—Methotrexate—colon cancer	0.0003	0.000901	CcSEcCtD
Trametinib—Body temperature increased—Methotrexate—colon cancer	0.0003	0.000901	CcSEcCtD
Trametinib—Asthenia—Methotrexate—colon cancer	0.000272	0.000817	CcSEcCtD
Trametinib—Pruritus—Methotrexate—colon cancer	0.000268	0.000806	CcSEcCtD
Trametinib—Diarrhoea—Methotrexate—colon cancer	0.000259	0.00078	CcSEcCtD
Trametinib—Dizziness—Methotrexate—colon cancer	0.000251	0.000753	CcSEcCtD
Trametinib—Vomiting—Methotrexate—colon cancer	0.000241	0.000724	CcSEcCtD
Trametinib—Rash—Methotrexate—colon cancer	0.000239	0.000718	CcSEcCtD
Trametinib—Dermatitis—Methotrexate—colon cancer	0.000239	0.000718	CcSEcCtD
Trametinib—Headache—Methotrexate—colon cancer	0.000237	0.000714	CcSEcCtD
Trametinib—Nausea—Methotrexate—colon cancer	0.000225	0.000677	CcSEcCtD
Trametinib—MAP2K2—Focal Adhesion—HRAS—colon cancer	0.000125	0.000246	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—AKT1—colon cancer	0.000125	0.000246	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—colon cancer	0.000125	0.000245	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—AKT1—colon cancer	0.000124	0.000244	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—HRAS—colon cancer	0.000124	0.000244	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—HRAS—colon cancer	0.000124	0.000244	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—HRAS—colon cancer	0.000124	0.000244	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—AKT1—colon cancer	0.000123	0.000243	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—NRAS—colon cancer	0.000123	0.000242	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—HRAS—colon cancer	0.000123	0.000241	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—colon cancer	0.000122	0.000241	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—AKT1—colon cancer	0.000122	0.00024	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	0.000122	0.00024	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—PPARG—colon cancer	0.000122	0.000239	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—HRAS—colon cancer	0.000121	0.000239	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—FGFR3—colon cancer	0.000121	0.000239	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—HRAS—colon cancer	0.000121	0.000238	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—SRC—colon cancer	0.00012	0.000236	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—PIK3CA—colon cancer	0.000118	0.000233	CbGpPWpGaD
Trametinib—MAP2K1—Insulin Signaling—AKT1—colon cancer	0.000118	0.000233	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—AKT1—colon cancer	0.000118	0.000232	CbGpPWpGaD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—AKT1—colon cancer	0.000117	0.000231	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—AKT1—colon cancer	0.000117	0.000231	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CA7—colon cancer	0.000117	0.000231	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—NRAS—colon cancer	0.000117	0.000231	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—HRAS—colon cancer	0.000117	0.000231	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—HRAS—colon cancer	0.000117	0.00023	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—AKT1—colon cancer	0.000117	0.00023	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—AKT1—colon cancer	0.000117	0.00023	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—AKT1—colon cancer	0.000117	0.00023	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—AKT1—colon cancer	0.000117	0.00023	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—AKT1—colon cancer	0.000116	0.000229	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—SRC—colon cancer	0.000116	0.000228	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—AKT1—colon cancer	0.000116	0.000228	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—NRAS—colon cancer	0.000115	0.000227	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—AKT1—colon cancer	0.000115	0.000226	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—colon cancer	0.000114	0.000225	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—AKT1—colon cancer	0.000114	0.000225	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—AKT1—colon cancer	0.000114	0.000224	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—colon cancer	0.000113	0.000223	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—VEGFA—colon cancer	0.000113	0.000222	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—EGFR—colon cancer	0.000112	0.000221	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—NRAS—colon cancer	0.000111	0.000219	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—AKT1—colon cancer	0.00011	0.000217	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—HRAS—colon cancer	0.00011	0.000216	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—AKT1—colon cancer	0.000109	0.000215	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—AKT1—colon cancer	0.000109	0.000215	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—AKT1—colon cancer	0.000109	0.000215	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—SRC—colon cancer	0.000108	0.000213	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—AKT1—colon cancer	0.000108	0.000213	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—KRAS—colon cancer	0.000108	0.000212	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—AKT1—colon cancer	0.000107	0.000211	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—AKT1—colon cancer	0.000107	0.00021	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—KRAS—colon cancer	0.000106	0.000209	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—colon cancer	0.000106	0.000209	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—VEGFA—colon cancer	0.000106	0.000208	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—EGFR—colon cancer	0.000105	0.000207	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—NRAS—colon cancer	0.000104	0.000205	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—AKT1—colon cancer	0.000103	0.000204	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—AKT1—colon cancer	0.000103	0.000203	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	0.000103	0.000202	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—EGFR—colon cancer	0.000101	0.0002	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—KRAS—colon cancer	0.000101	0.000199	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—KRAS—colon cancer	9.91e-05	0.000195	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—PIK3CA—colon cancer	9.9e-05	0.000195	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—PIK3CA—colon cancer	9.73e-05	0.000192	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—AKT1—colon cancer	9.67e-05	0.000191	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—KRAS—colon cancer	9.59e-05	0.000189	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—EGFR—colon cancer	9.49e-05	0.000187	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—PIK3CA—colon cancer	9.26e-05	0.000182	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD8A—colon cancer	9.22e-05	0.000182	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—HRAS—colon cancer	9.16e-05	0.00018	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—CTNNB1—colon cancer	9.14e-05	0.00018	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—PIK3CA—colon cancer	9.11e-05	0.000179	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—HRAS—colon cancer	9e-05	0.000177	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—KRAS—colon cancer	8.97e-05	0.000177	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD8A—colon cancer	8.62e-05	0.00017	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—HRAS—colon cancer	8.57e-05	0.000169	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—CTNNB1—colon cancer	8.55e-05	0.000168	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—EP300—colon cancer	8.5e-05	0.000167	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—HRAS—colon cancer	8.42e-05	0.000166	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—SRC—colon cancer	8.26e-05	0.000163	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—HRAS—colon cancer	8.15e-05	0.000161	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CTNNB1—colon cancer	8.07e-05	0.000159	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—VEGFA—colon cancer	8.05e-05	0.000159	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—AKT1—colon cancer	7.95e-05	0.000157	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—EP300—colon cancer	7.95e-05	0.000157	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—NRAS—colon cancer	7.95e-05	0.000157	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CDKN1A—colon cancer	7.89e-05	0.000155	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—BCL2L1—colon cancer	7.89e-05	0.000155	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—SRC—colon cancer	7.73e-05	0.000152	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—HRAS—colon cancer	7.62e-05	0.00015	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CTNNB1—colon cancer	7.55e-05	0.000149	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—FGFR3—colon cancer	7.54e-05	0.000149	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—VEGFA—colon cancer	7.53e-05	0.000148	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—EP300—colon cancer	7.5e-05	0.000148	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—AKT1—colon cancer	7.44e-05	0.000147	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—NRAS—colon cancer	7.44e-05	0.000147	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—TGFB1—colon cancer	7.39e-05	0.000146	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CDKN1A—colon cancer	7.38e-05	0.000145	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—BCL2L1—colon cancer	7.38e-05	0.000145	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—SRC—colon cancer	7.3e-05	0.000144	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—EGFR—colon cancer	7.24e-05	0.000143	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ODC1—colon cancer	7.1e-05	0.00014	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CHST5—colon cancer	7.1e-05	0.00014	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—FGFR3—colon cancer	7.05e-05	0.000139	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—EP300—colon cancer	7.02e-05	0.000138	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—NRAS—colon cancer	7.02e-05	0.000138	CbGpPWpGaD
Trametinib—MAP2K2—Disease—FGFR3—colon cancer	6.96e-05	0.000137	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TGFB1—colon cancer	6.91e-05	0.000136	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—KRAS—colon cancer	6.84e-05	0.000135	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—SRC—colon cancer	6.83e-05	0.000135	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—EGFR—colon cancer	6.78e-05	0.000133	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—NRAS—colon cancer	6.57e-05	0.000129	CbGpPWpGaD
Trametinib—MAP2K1—Disease—FGFR3—colon cancer	6.51e-05	0.000128	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—KRAS—colon cancer	6.4e-05	0.000126	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—EGFR—colon cancer	6.4e-05	0.000126	CbGpPWpGaD
Trametinib—MAP2K2—Disease—APC—colon cancer	6.39e-05	0.000126	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CDH1—colon cancer	6.37e-05	0.000125	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—KRAS—colon cancer	6.04e-05	0.000119	CbGpPWpGaD
Trametinib—MAP2K2—Disease—BRAF—colon cancer	6.01e-05	0.000118	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—EGFR—colon cancer	5.98e-05	0.000118	CbGpPWpGaD
Trametinib—MAP2K1—Disease—APC—colon cancer	5.98e-05	0.000118	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDH1—colon cancer	5.96e-05	0.000117	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—HRAS—colon cancer	5.81e-05	0.000115	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—KRAS—colon cancer	5.65e-05	0.000111	CbGpPWpGaD
Trametinib—MAP2K1—Disease—BRAF—colon cancer	5.62e-05	0.000111	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—PIK3CA—colon cancer	5.55e-05	0.000109	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—colon cancer	5.46e-05	0.000108	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—HRAS—colon cancer	5.44e-05	0.000107	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—PIK3CA—colon cancer	5.19e-05	0.000102	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—HRAS—colon cancer	5.14e-05	0.000101	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—AKT1—colon cancer	5.13e-05	0.000101	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FGFR3—colon cancer	4.87e-05	9.6e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTGS2—colon cancer	4.85e-05	9.56e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—HRAS—colon cancer	4.8e-05	9.47e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—AKT1—colon cancer	4.8e-05	9.46e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CTNNB1—colon cancer	4.7e-05	9.26e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CDKN1A—colon cancer	4.59e-05	9.05e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FGFR3—colon cancer	4.56e-05	8.98e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTGS2—colon cancer	4.54e-05	8.94e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—AKT1—colon cancer	4.53e-05	8.93e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—APC—colon cancer	4.47e-05	8.82e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—NRAS—colon cancer	4.47e-05	8.82e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CTNNB1—colon cancer	4.4e-05	8.67e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EP300—colon cancer	4.37e-05	8.61e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CTNNB1—colon cancer	4.34e-05	8.55e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDKN1A—colon cancer	4.3e-05	8.47e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	4.3e-05	8.46e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—SRC—colon cancer	4.25e-05	8.37e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—AKT1—colon cancer	4.24e-05	8.36e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CDKN1A—colon cancer	4.24e-05	8.36e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—BRAF—colon cancer	4.21e-05	8.29e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—APC—colon cancer	4.19e-05	8.25e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—NRAS—colon cancer	4.19e-05	8.25e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EP300—colon cancer	4.09e-05	8.06e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—NRAS—colon cancer	4.09e-05	8.06e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—EGFR—colon cancer	4.08e-05	8.03e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CTNNB1—colon cancer	4.06e-05	8e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EP300—colon cancer	4.04e-05	7.95e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—SRC—colon cancer	3.98e-05	7.83e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CDKN1A—colon cancer	3.97e-05	7.82e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—BRAF—colon cancer	3.94e-05	7.75e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—SRC—colon cancer	3.92e-05	7.73e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—KRAS—colon cancer	3.85e-05	7.59e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—NRAS—colon cancer	3.83e-05	7.54e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—EGFR—colon cancer	3.81e-05	7.51e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EP300—colon cancer	3.78e-05	7.44e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NRAS—colon cancer	3.77e-05	7.44e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EGFR—colon cancer	3.73e-05	7.34e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—SRC—colon cancer	3.67e-05	7.23e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—KRAS—colon cancer	3.6e-05	7.1e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—colon cancer	3.57e-05	7.04e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CA—colon cancer	3.54e-05	6.97e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NRAS—colon cancer	3.53e-05	6.96e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KRAS—colon cancer	3.52e-05	6.93e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MYC—colon cancer	3.52e-05	6.93e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TGFB1—colon cancer	3.51e-05	6.91e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ABCB1—colon cancer	3.5e-05	6.89e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EGFR—colon cancer	3.49e-05	6.87e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EGFR—colon cancer	3.44e-05	6.78e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—TYMS—colon cancer	3.43e-05	6.76e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CA—colon cancer	3.31e-05	6.52e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KRAS—colon cancer	3.29e-05	6.49e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MYC—colon cancer	3.29e-05	6.48e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TGFB1—colon cancer	3.28e-05	6.47e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—HRAS—colon cancer	3.27e-05	6.45e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KRAS—colon cancer	3.25e-05	6.4e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PIK3CA—colon cancer	3.23e-05	6.37e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EGFR—colon cancer	3.22e-05	6.34e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CASP3—colon cancer	3.15e-05	6.21e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCND1—colon cancer	3.07e-05	6.05e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—HRAS—colon cancer	3.06e-05	6.03e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CTNNB1—colon cancer	3.04e-05	5.99e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—KRAS—colon cancer	3.04e-05	5.99e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CA—colon cancer	3.02e-05	5.96e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HRAS—colon cancer	2.99e-05	5.89e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CA—colon cancer	2.98e-05	5.88e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CDKN1A—colon cancer	2.97e-05	5.85e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CASP3—colon cancer	2.95e-05	5.81e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—AKT1—colon cancer	2.89e-05	5.7e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCND1—colon cancer	2.87e-05	5.66e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CTNNB1—colon cancer	2.84e-05	5.6e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EP300—colon cancer	2.83e-05	5.57e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HRAS—colon cancer	2.8e-05	5.51e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CA—colon cancer	2.79e-05	5.5e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CDKN1A—colon cancer	2.78e-05	5.47e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HRAS—colon cancer	2.76e-05	5.44e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SRC—colon cancer	2.75e-05	5.41e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—AKT1—colon cancer	2.7e-05	5.33e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VEGFA—colon cancer	2.68e-05	5.27e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EP300—colon cancer	2.64e-05	5.21e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NRAS—colon cancer	2.64e-05	5.21e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.64e-05	5.21e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—AKT1—colon cancer	2.64e-05	5.2e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HRAS—colon cancer	2.58e-05	5.09e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SRC—colon cancer	2.57e-05	5.06e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VEGFA—colon cancer	2.5e-05	4.93e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NRAS—colon cancer	2.47e-05	4.87e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—AKT1—colon cancer	2.47e-05	4.87e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MYC—colon cancer	2.46e-05	4.85e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TGFB1—colon cancer	2.46e-05	4.84e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—AKT1—colon cancer	2.44e-05	4.8e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PPARG—colon cancer	2.43e-05	4.79e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGFR—colon cancer	2.41e-05	4.75e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MYC—colon cancer	2.3e-05	4.54e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TGFB1—colon cancer	2.3e-05	4.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—AKT1—colon cancer	2.28e-05	4.49e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KRAS—colon cancer	2.28e-05	4.48e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGFR—colon cancer	2.25e-05	4.44e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KRAS—colon cancer	2.13e-05	4.19e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CA—colon cancer	2.09e-05	4.12e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—colon cancer	2.02e-05	3.98e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CA—colon cancer	1.96e-05	3.85e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HRAS—colon cancer	1.93e-05	3.81e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTGS2—colon cancer	1.91e-05	3.77e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—colon cancer	1.89e-05	3.73e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ABCB1—colon cancer	1.88e-05	3.7e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TYMS—colon cancer	1.84e-05	3.63e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HRAS—colon cancer	1.81e-05	3.56e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKT1—colon cancer	1.71e-05	3.36e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKT1—colon cancer	1.6e-05	3.15e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—EP300—colon cancer	1.59e-05	3.13e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PPARG—colon cancer	1.31e-05	2.57e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CA—colon cancer	1.18e-05	2.32e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTGS2—colon cancer	1.03e-05	2.02e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AKT1—colon cancer	9.61e-06	1.89e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—EP300—colon cancer	8.54e-06	1.68e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CA—colon cancer	6.32e-06	1.24e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKT1—colon cancer	5.16e-06	1.02e-05	CbGpPWpGaD
